Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.

NCT01878890 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumors
Non-Hodgkin's Lymphoma

Interventions

DRUG: Efavirenz 600mg
DRUG: Efavirenz 1200 mg
DRUG: Efavirenz 1800 mg
DRUG: Efavirenz 2200 mg

Sponsor

Institut Bergonié